UNICOCELL BIOMED CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.8 TWD | -2.22% |
|
-5.42% | +0.96% |
| Mar. 07 | UnicoCell Biomed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 1,615 | 1,636 | 1,356 | 4,603 |
| Enterprise Value (EV) 1 | 1,417 | 1,516 | 1,208 | 4,200 |
| P/E ratio | -14 x | -18.9 x | -14.5 x | -53.1 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 406 x | 200 x | 94.2 x | 187 x |
| EV / Revenue | 356 x | 185 x | 83.9 x | 171 x |
| EV / EBITDA | -14.4 x | -21.3 x | -15.8 x | -54.8 x |
| EV / FCF | -13.1 x | -28 x | -24.5 x | -77.5 x |
| FCF Yield | -7.65% | -3.57% | -4.08% | -1.29% |
| Price to Book | 4.7 x | 6.22 x | 4.06 x | 7.75 x |
| Nbr of stocks (in thousands) | 37,564 | 37,775 | 42,361 | 55,460 |
| Reference price 2 | 43.00 | 43.30 | 32.00 | 83.00 |
| Announcement Date | 1/22/22 | 3/15/22 | 4/14/23 | 3/7/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.492 | 15.74 | 3.982 | 8.177 | 14.4 | 24.59 |
| EBITDA 1 | -63.89 | -91.63 | -98.68 | -71.24 | -76.25 | -76.71 |
| EBIT 1 | -69.01 | -101.1 | -111.4 | -87.34 | -92.11 | -96.28 |
| Operating Margin | -1,256.52% | -642.23% | -2,796.33% | -1,068.08% | -639.78% | -391.56% |
| Earnings before Tax (EBT) 1 | -68.84 | -100.9 | -109.2 | -86.37 | -91.16 | -84.11 |
| Net income 1 | -68.84 | -100.9 | -109.2 | -86.37 | -91.16 | -84.11 |
| Net margin | -1,253.4% | -641.41% | -2,742.57% | -1,056.3% | -633.15% | -342.06% |
| EPS 2 | -4.262 | -3.326 | -3.075 | -2.292 | -2.200 | -1.564 |
| Free Cash Flow 1 | -39.81 | -94.41 | -108.4 | -54.15 | -49.26 | -54.17 |
| FCF margin | -724.82% | -599.93% | -2,721.87% | -662.21% | -342.13% | -220.32% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/10/20 | 12/10/20 | 1/22/22 | 3/15/22 | 4/14/23 | 3/7/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 253 | 191 | 198 | 119 | 147 | 403 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -39.8 | -94.4 | -108 | -54.1 | -49.3 | -54.2 |
| ROE (net income / shareholders' equity) | -33.6% | -35.6% | -34.2% | -28.5% | -30.5% | -18.1% |
| ROA (Net income/ Total Assets) | -20.2% | -19.7% | -18.6% | -15.8% | -16.2% | -10.9% |
| Assets 1 | 341.2 | 513.1 | 586.4 | 545.1 | 563.7 | 768.9 |
| Book Value Per Share 2 | 9.750 | 9.200 | 9.140 | 6.960 | 7.880 | 10.70 |
| Cash Flow per Share 2 | 9.030 | 7.060 | 5.910 | 3.460 | 1.270 | 0.3600 |
| Capex 1 | 8.69 | 50.8 | 56.7 | 23.6 | 14.5 | 15.8 |
| Capex / Sales | 158.19% | 322.58% | 1,423.58% | 289.04% | 100.38% | 64.26% |
| Announcement Date | 12/10/20 | 12/10/20 | 1/22/22 | 3/15/22 | 4/14/23 | 3/7/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +0.96% | 145M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- 6794 Stock
- Financials UnicoCell Biomed Co., Ltd.
